Valuation : Hemostemix Inc.

Market Cap 15.86M 11.48M 9.88M 9.29M 8.48M 1.09B 15.91M 110M 42.57M 556M 43.13M 42.18M 1.77B P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 18.72M 13.56M 11.66M 10.96M 10.01M 1.28B 18.78M 130M 50.25M 657M 50.91M 49.79M 2.09B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
86%
Yield 2024 *
-
Yield 2025 -
1 month+7.14%
3 months+50.00%
6 months-6.25%
Current year-16.67%
1 week 0.07
Extreme 0.07
0.08
1 month 0.06
Extreme 0.065
0.08
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.14
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5
Manager TitleAgeSince
Chief Executive Officer - 09/02/2020
Director of Finance/CFO - 04/03/2020
Chief Tech/Sci/R&D Officer - 13/10/2021
Director TitleAgeSince
Director/Board Member - 25/11/2019
Director/Board Member 67 08/02/2020
Director/Board Member - 07/04/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/07/26 Option

Chairman

525,000 0.2654%
22/07/26 Option

Director

385,000 0.1946%
22/07/26 Option

Founder

1,730,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-28.57%-37.50% 11.48M
-0.38%-0.99%+42.69%+100.85% 67.82B
-2.71%-0.71%+35.89%+81.43% 63.22B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
+0.54%-1.50%+25.04%+14.15% 25.38B
-1.11%+0.90%+22.24%-18.50% 19.89B
+1.15%-5.02%+219.82%+379.02% 17.4B
-0.73%-0.61%-7.54%+523.30% 14.95B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.29%+1.51%+34.46%+157.23% 27.69B
Weighted average by Cap. -0.67%+0.90%+36.87%+140.28%

Financials

2024 2025
Net sales - -
Net income -2.62M -1.89M -1.63M -1.53M -1.4M -179M -2.62M -18.17M -7.02M -91.76M -7.12M -6.96M -292M -4.71M -3.41M -2.94M -2.76M -2.52M -323M -4.73M -32.74M -12.65M -165M -12.82M -12.54M -527M
Net Debt 4.23M 3.06M 2.63M 2.48M 2.26M 290M 4.24M 29.38M 11.36M 148M 11.51M 11.25M 473M 2.86M 2.07M 1.78M 1.68M 1.53M 196M 2.87M 19.87M 7.68M 100M 7.78M 7.61M 320M
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
04/09/26 CA$0.0750 0.00% 2,777
03/09/26 CA$0.0750 +7.14% 2,978
02/09/26 CA$0.0700 0.00% 5,001
01/09/26 CA$0.0700 -6.67% 22,844
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!